How are energy investors positioned?
NEW YORK - LifeMD, Inc. (NASDAQ: LFMD), a telehealth company with impressive revenue growth of 43% over the last twelve months and a market capitalization of approximately $490 million, has launched a limited-time offer for a weight management bundle, including Wegovy® (semaglutide) and a virtual weight loss program, priced at $299 for the first month. This introductory offer for new self-pay patients is part of LifeMD’s collaboration with Novo Nordisk, aiming to provide an integrated care experience for those seeking FDA-approved alternatives to compounded therapies.
The bundle, announced today, includes the medication Wegovy® at a discounted price of $199, facilitated through LifeMD’s integration with NovoCare® Pharmacy. An additional $100 covers the cost of clinical care, onboarding, and ongoing support within LifeMD’s virtual weight management program. After the introductory month, the program’s cost will increase to $599 per month, with no long-term commitment required. Eligible patients must be prescribed Wegovy® on or before June 30, 2025, to avail of the offer.
LifeMD’s Chairman and CEO, Justin Schreiber, emphasized the collaboration’s role in enhancing affordability and access to medically guided weight loss solutions. Dave Moore, Executive Vice President, US Operations of Novo Nordisk, also highlighted the partnership’s potential to improve patient access and outcomes nationwide. According to InvestingPro data, LifeMD maintains an impressive gross profit margin of 88%, though the company is yet to achieve profitability. Analysts expect the company to turn profitable this year.
The weight management program offered by LifeMD delivers personalized care, leveraging its platform which includes a 50-state medical group and national diagnostic lab partnerships. This ensures a continuous care model from virtual consultation to prescription fulfillment and ongoing coaching.
Wegovy® is recognized as the first GLP-1 therapy in the U.S. approved for chronic weight management and cardiovascular risk reduction in adults with obesity. It is available by prescription for eligible LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications.
LifeMD, Inc. is a provider of virtual primary care services, offering telemedicine and access to laboratory and pharmacy services across various health conditions. The company operates with a vertically integrated digital care platform, a 50-state affiliated medical group, and a patient care center to facilitate access to quality care. The stock has shown strong momentum, trading near its 52-week high of $11.39, with a remarkable year-to-date return of over 117%. InvestingPro analysis reveals 14 additional key insights about LifeMD’s financial health and market position, available to subscribers.
This news article is based on a press release statement and contains no promotional content.
In other recent news, LifeMD Inc. reported impressive first-quarter financial results for 2025, with total revenue reaching $65.7 million, a 49% increase year-over-year. This figure surpassed both BTIG and consensus estimates, which stood at $63.4 million and $62.5 million, respectively. The company’s adjusted EBITDA also exceeded expectations, coming in at approximately $8.7 million, compared to BTIG’s forecast of $6.8 million. Cantor Fitzgerald maintained its Overweight rating on LifeMD, with a price target of $15.00, following the company’s earnings beat. The firm’s analyst highlighted improved customer retention as a key factor in the positive results. BTIG also maintained a Buy rating with a $12.00 price target, noting the significant revenue beat was largely due to healthcare product sales, particularly obesity-related products. LifeMD’s management has revised its full-year 2025 guidance upwards, with revenue projections now set between $268 million and $275 million, and EBITDA forecasts adjusted to $31-$33 million. The company’s expansion into new healthcare verticals, such as women’s health and behavioral health, was also emphasized as a strategic move to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.